ENTITY
Acadia Pharmaceuticals

Acadia Pharmaceuticals (ACAD US)

24
Analysis
Health CareUnited States
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.
more
Refresh
15 Jun 2020 12:13

SK Biopharm Valuation Analysis (What Is the Market Implying from SK Holdings?)

In this insight, we provide a valuation analysis of SK Biopharmaceuticals (BIO SK).Bullish Case Valuation - If we take a bullish case valuation...

Logo
334 Views
Share
19 May 2020 22:44

SK Biopharm IPO Preview

SK Biopharmaceuticals (BIO SK) is getting ready to complete an IPO in the Korean stock market in June. The SK Biopharm will be one of the biggest...

Logo
228 Views
Share
bearishS&P 500 INDEX
22 Apr 2020 08:38

U.S. Equity Strategy: Several Indicators Suggest a Pullback Likely

Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight...

Logo
440 Views
Share
bullishS&P 500 INDEX
11 Mar 2020 05:05

S&P 500: Long-Term Oversold

Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&P 500 (2,855), DJI (24,681) and Russell...

Logo
331 Views
Share
05 Mar 2020 10:35

A Bottom Has Been Established; Possible Retest?

In today’s report we outline  our belief that the combination of extreme oversold conditions and several key sectors/industries holding above major...

Logo
364 Views
Share
x